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Epidermal growth factor receptor (EGFR) is one of the key molecules in cell growth and multiplication 
and plays an important role in some malignant processes. L2 domain of extra-cellular part of this 
receptor involved in ligand binding and its inhibition can prevent activation of related signaling 
pathways. The aim of the present study was cloning and expressing the fragment coding for L2 region 
of human EGFR for the production of recombinant L2 protein. The total RNA from A431 cells line was 
extracted and used for amplification of the sequence coding for L2 domain of EGFR by reverse 
transcriptase-polymerase chain reaction (RT-PCR) technique. The product was cloned into the PGEM-T 
vector and used for sequencing. In the next step, the insert was removed from the PGEM-T vector and 
subcloned into the PET22 expression vector. The expression construct was transformed into the 
Escherichia coli BL21 (DE3) and recombinant protein expression was analyzed by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Analyzing the expression of produced 
recombinant protein showed that the recombinant L2 can be highly expressed by this expression 
system. This recombinant protein can be used for the production of specific mAb, screening for 
specific ligands and competitive inhibition of the EGFR.  
 





Epidermal growth factor receptor (EGFR) belongs to a 
family of receptors also known as the type I receptor 
tyrosine kinases (Baselga, 2002). Activation of this 
receptor triggers multiple cellular events leading to cell 
proliferation, differentiation, migration, protection from 
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Abbreviations: EGFR, Epidermal growth factor receptor; RT-
PCR, reverse transcriptase-polymerase chain reaction; SDS-
PAGE, sodium dodecyl sulfate polyacrylamide gel 
electrophoresis; CR, cysteine rich; DEPC, diethylpyrocarbonate; 
BLAST, basic alignment search tools; LB, Luria-Bertani; IPTG, 
isopropyl-D-thiogalactopyranoside. 
Occurrence of mutation in the EGFR has been reported 
in several tumors (Salomon et al., 1995) and it’s over 
expression having been shown in head and neck, lung 
and colon cancers. This over expression has been 
correlated with poor survival of patients (Brabender et al., 
2001), whereas its inhibition was associated with inhibition 
of the xenograft of head and neck tumors (Carter et al., 
1992; Chen et al., 1987; Drebin et al., 1985; Goldstein et 
al., 1995). These findings indicated the importance of 
EGFR in certain cancers and show that this molecule can 
be considered as a target for designing specific inhibitors 
(Li et al., 2008).  
Three types of strategies have been developed for 
targeting of the EGFR according to the locations where 
the action takes place: at the intracellular tyrosine kinase 
domain, at the transmembrane lipophilic domain and at 





1997; Boonstra et al., 1995; Callaghan et al., 1993; 
Carpenter and Cohen, 1990; Ullrich et al., 1984). The 
extracellular part is composed of 621 amino acids 
containing four domains; two large homologous domains 
(L1 and L2) and two cysteine rich (CR) domains which 
referred to the CR1 and CR2 domains (Abe et al., 1998). 
The L1 and L2 subdomains are involved in the binding of 
ligands to the EGFR with high affinity (Ferguson, 2004). It 
has been shown that L2 domain plays a crucial role in 
ligand binding and activation of intracellular signaling 
pathway which initiates after binding of ligands to L2 
domain. Therefore, targeting of the L2 domain through 
designing specific inhibitors or production of monoclonal 
antibodies can effectively be used for EGFR blockage. 
The current method for production of anti-EGFR 
antibodies or other inhibitors uses whole or extracellular 
part of EGFR which have been associated with low 
efficiency. The objective of this study was to clone and 
express L2 domain of human EGFR in Escherichia coli 
for the production of recombinant L2 protein. 
 
 
MATERIALS AND METHODS 
 
Cell culture and RNA isolation 
 
In this study, the A431 cancer cells that express high levels of 
EGFR were used as a source of EGFR mRNA. The cell line was 
obtained from the American Type Culture Collection and cultured as 
described (Pourabbas et al., 2009). Briefly, the cells were cultured 
in tissue culture flasks in RPMI 1640 medium containing L-
glutamine (2 mM) (Sigma, Germany) supplemented with 10% heat-
inactivated fetal calf serum and penicillin/streptomycin.  
Total RNA was extracted from A431 cancer cells using RNAzol 
solution according to the manufacturer's instructions. Briefly, 10-6 
cells were homogenized in 1 ml of RNAzol solution and mixed with 
200 µl chloroform. The mixture was centrifuged in 12000 rpm for 15 
min and RNA from aqueous phase was precipitated by equal 
volume of isopropanol. The sediment was dissolved in diethylpyro-
carbonate (DEPC) treated distilled water after washing with 75% 
ethanol and drying.  
 
 
cDNA synthesis and PCR amplification of L2 domain 
 
6 µl of total RNA was entered in a reverse transcriptase (RT) 
reaction containing 1 µl oligo-dT primer, 4 µl of 5X buffer, 1 µl 
Ribobloc, 2 µl dNTPs and 1 µl of MMLV reverse transcriptase. The 
reaction was performed at 42°C for 60 min. 1 µl of prepared cDNA 
was subjected to polymerase chain reaction (PCR) amplification 
with primer pair L2-F: 5'-TACATATGCGCAAAGTGTGTAACGG 
AATAG-3' and L2-R 5'-TGCTCGAGCAAGTTCTTGTTTCCTGAA 
ATTATC-3' which was complementary to 5’ and 3’ ends of L2 
domain of human EGFR gene, respectively. PCR amplification was 
carried out in a final volume of 25 l containing PCR buffer (1X), 2 
mM MgCl2, a 0.2 mM concentration of each 2-deoxynucleoside 
triphosphate (dATP, dCTP, dTTP and dGTP), a 0.4 M concen-
tration of each primer and 2.5 U of Pfu DNA polymerase (Fermentas 
Inc.). PCR conditions were: primary denaturation at 94°C for 4 min 
followed by 30 cycles of denaturation at 94°C for1 min, annealing at 
60°C for 1 min, extension at 72°C for 1 min and a final extension at 
72°C for 7min. The reaction further incubated for 20 min with Taq 
DNA polymerase for 3’ end tailing with single A base.  




Cloning and sequencing of L2 domain gene 
 
The PCR product purified with a PCR purification kit (Qiagen) 
according to the manufacturer’s instructions and used for T-A 
cloning using pGEM-T easy cloning kit (Promega), yielded the 
plasmid clone pGEM-L2. The reaction was transformed into an 
E. coli, DH5a competent cells and a positive clone was submitted 
for sequencing. Nucleotide and predicted amino acid sequences 
were compared to data available by the basic alignment search 
tools (BLAST) search method. 
 
 
Recombinant expression of L2 domain in E. coli 
 
The coding region for L2 domain was isolated by digestion of 
pGEM-L2 clones with NdeI-XhoI restriction enzymes and subcloned 
into the pET 22 b expression vector (Novagen) in frame with a 
carboxy-terminal six histidine tag, yielding the plasmid subclone 
pET22b-L2. The construct was transformed into E. coli Bl21 strain, 
cultured at 37°C in Luria-Bertani (LB) medium containing 100 µg 
ml-1 ampicillin to an absorbance at 600 nm (A600) of 0.7. Protein 
expression was induced by adding isopropyl--D-thiogalacto-
pyranoside (IPTG) to a final concentration of 1 mM and analyzed by 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE). 
Purification of recombinant L2 was carried out as described 
(Kafshnochi et al, 2010). Briefly,  500 ml LB media containing 100 µg 
ml-1 ampicillin was inoculated with 5 ml of an overnight culture of 
recombinant bacteria and incubated at 37°C with vigorous shaking 
(150 rpm). Culture were induced at mid-log phase by adding 0.125 
mM IPTG and growth was continued for 6 h. Bacteria was 
harvested (10000 x g, for 10 min), resuspended in 10 ml lysis buffer 
A (50 mM NaH2PO4, pH-8, 300 mM NaCl, 10 mM imidazole, 1 
mg/ml lysozyme) and disrupted by sonication (five 30 s pulses 
interrupted with cooling on ice). Soluble and insoluble fraction was 
separated by centrifugation at 12000 x g for 10 min at 4°C and 
recombinant protein was found to be mainly in the insoluble fraction 





SDS-PAGE was performed using the Laemmli buffer system. Prior 
to electrophoresis, the samples were heated at 100°C for 10 min in 
dissociating buffer containing 2% SDS and 5% 2-mercaptoethanol. 
Protein markers used were phosphorylase (97.4 kDa), bovine serum 
albumin 66.3 kDa), ovalbumin (45.0 kDa), lactate dehydrigenae 35.0 






E. coli BL21 cells transformed with pET 22b-L2 were grown in liquid 
medium at different inducer concentrations and induction times to 
check their ability to higher level of expression. After 1, 3, 6, 12 and 
24 h induction, 1 ml of bacterial culture was centrifuged and the 





Amplification, cloning and sequencing of L2 domain 
of human EGFR  
 
The amplification of L2 domain of human EGFR by RT- 
PCR resulted in  the  production  of  a  specified  band  of 



















































Figure 2. Subcloning of L2 fragment in pET 22 b 
expression vector. Lanes 1, 3 and 5 represent 3 
pET22b-L2 clones before restriction digestion and 
lanes 2, 4 and 6, represent same clones after 





about 410 bp (Figure 1). The PCR product was ligated to 
pGEM-Teasy vector and cloning was verified by PCR and 
restriction digestion analysis (Figure 2). Sequencing and 
multiple alignment of nucleotide and predicted amino acid 







Figure 3. Recombinant expression of L2 coding region in E. 
coli BL21. Lane 1, before induction; lane 2, after induction 




the identity of clone as showed 100% homology with L2 
domain of human EGFR. 
 
 
Recombinant expression and purification of L2 
domain  
 
For high-level expression of L2 protein in E. coli, the L2 
insert was removed from pGEM-T vector and subcloned 
into the pET 22 b expression vector (Figure 3). The 
nucleotide sequence of this construct was confirmed by 
sequence analysis. Induction with IPTG of E. coli BL21 
transformed with expression cassette pET 22 b-L2 
resulted in a high level expression of recombinant protein 
as appeared in SDS-PAGE analysis of lysate of induced 
bacteria. Figure 4 shows Commassie blue-stained SDS-
PAGE gels of E. coli culture before and after induction. 
Recombinant L2 protein was expressed as a 16 - 18 KDa 
protein in high concentration. 
 
 
Optimization of recombinant protein expression 
 
The optimal IPTG concentration for production of recom-
binant L2 was 0.125 mM (Figure 4). Thus, the best 
conditions for the maximum production of recombinant L2 
by E. coli BL21 were: incubation of the recombinant cells 
at 37°C in the presence of 0.125 mM concentration of 















Figure 4. Effect of different IPTG concentration on the level 
of recombinant L2 expression. Lane 1, lysate of E. coli BL21 
containing pET22-L2 before induction; lanes 2 - 5, the same 
expression after induction with IPTG concentration of 






Conventional methods used for treatment of cancer affect 
non-selectively, both normal and cancerous cells and 
leads to severe side effects. Recent studies in oncology 
focused on molecular events and key molecules that are 
involved in cell growth, differentiation and migration 
(Roskoski, 2004; Woodburn, 1999). The objective of such 
studies is the development of therapeutics that selectively 
target molecules expressed differentially on malignant 
cells without affecting normal cells. Growth factors and 
their receptors are among the molecules that are involved 
in cell multiplication processes and seem as good targets 
for interventional therapies. EGFR is a receptor tyrosine 
kinase that expresses in a significantly higher level in 
several types of cancer cells and its activation results in 
cell proliferation, differentiation, cell adhesion, migration 
and angiogenesis. Ultrastructural studies have shown 
that L2 domain from extracellular part of EGFR is 
involved in ligand binding and receptor activation (Li et 
al., 2008). It has being shown that monoclonal antibodies 
such as Cetuximab that binds to L2 domain of EGFR can 
block and inhibits receptor activation. These findings 
indicated that l2 domain could be considered as a target 
for the development of specific inhibitors. Furthermore, 
soluble L2 can be used for competitive inhibition of EGFR 
by collecting ligands accessible for cell surface EGFR. 
Thus, the L2 domain is an important molecule in 
researches related to EGFR and  production  of  recombi- 




nant L2 would be useful for further applications in cancer 
research. 
For the production of recombinant L2, the A431 cell 
was used as a source of EGFR mRNA. The A431 cell is 
a human epithelial carcinoma cell line that expresses 
EGFR in very high concentration (Rizzino et al., 1988). 
The RNA extracted from these cells was used for cDNA 
synthesis and RT-PCR amplification of L2 coding region 
by standard method (Schmidt, 2004). The T-A cloning 
method was used for cloning of the PCR product. It has 
being shown that this method is a rapid and efficient 
method for cloning of PCR product for further use in 
reactions such as sequencing, expression and any other 
studies. Sequencing of the cloned gene showed 100% 
nucleotide homology with domain L2 of EGFR and 
confirmed the identity of the clone. Recombinant expression 
of L2 fragment was carried out by E. coli BL21 and pET 
22 b expression vector which carry T7 promoter. SDS 
PAGE analysis of induced cells revealed that this system 
is capable of producing a high level of recombinant L2.  
Different expression systems have been developed for 
recombinant expression of proteins, including E. coli 
prokaryotic system, yeast expression system, insect and 
mammalian cell expression systems. Each of these 
systems has their own advantage and disadvantages 
(Sambrook and Russell, 2001). It has being shown that 
E. coli system is a very rapid, inexpensive and efficient 
system for production of recombinant proteins (Li et al., 
2008). But this system does not contain posttranslational 
modification mechanisms such as, glycosylation, 
phosphorylation, acetylation and carboxylation. Thus, this 
system cannot be used for the production of recombinant 
proteins; thus, posttranslational modification is necessary 
for their correct structure/function. In case of L2 domain, 
sequence analysis showed that this domain does not 
have any site for such posttranslational modification. So, 
E. coli could be a suitable expression system for the 
production of recombinant L2. Findings of our study 
indicated that L2 domain are stably expressed in E. coli 
and can be purified for further use in applications such as 
production of monoclonal antibodies, screening for specific 
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